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Abstract 21 
Clostridium difficile is an anaerobic, Gram positive and spore forming bacterium 22 
that is the leading worldwide infective cause of hospital-acquired and antibiotic-23 
associated diarrhea. Several studies have reported associations between 24 
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humoral immunity and the clinical course of C. difficile infection (CDI). Host 25 
humoral immune responses are determined using conventional enzyme-linked 26 
immunosorbant assay (ELISA) techniques. Herein, we report the first use of a 27 
novel protein microarray assay to determine systemic IgG antibody responses 28 
against a panel of highly purified C. difficile-specific antigens, including native 29 
toxins A and B (TcdA and TcdB), recombinant fragments of toxins A and B (TxA4 30 
and TxB4), ribotype-specific surface layer proteins (SLPs; 001, 002, 027) and 31 
control proteins (tetanus and candida). Microarrays were probed with sera from a 32 
total of 327 individuals with CDI, cystic fibrosis without diarrhea, and healthy 33 
controls. For all antigens, precision profiles demonstrated <10% coefficient of 34 
variation (CV). Significant correlation was observed between microarray and 35 
ELISA in the quantification of anti-toxin A and -B IgG. These results indicate that 36 
microarray is a suitable assay for defining humoral immune responses to C. 37 
difficile protein antigens and may have potential advantages in throughput, 38 
convenience and cost.  39 
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Introduction 42 
Clostridium difficile is the leading worldwide infective cause of hospital-acquired 43 
and antibiotic-associated diarrhea, imposing a considerable financial burden on 44 
health service providers in both Europe and the USA [1-3]. Infection causes a 45 
spectrum of clinical presentations, ranging from an asymptomatic carrier state to 46 
severe fulminant colitis and death [4]. Following successful treatment, an 47 
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estimated 20-30% of patients with primary C. difficile infection (CDI) develop 48 
recurrence of symptoms, either caused by relapse of the original infection or 49 
reinfection with a new strain [5].  50 
 51 
This anaerobic and spore-forming bacterium exerts its major pathological effects 52 
through two pro-inflammatory and cytotoxic protein exotoxins, TcdA (toxin A) and 53 
TcdB (toxin B) [6]. Non-toxin virulence factors such as surface layer proteins 54 
(SLPs) and cell wall proteins (CWPs) have also been described, and may play a 55 
role in disease expression [7-9]. 56 
 57 
The majority of healthy adults have detectable antibodies to C. difficile TcdA and 58 
TcdB in their serum that are thought to arise from colonization in infancy or from 59 
repeated exposure to C. difficile in adulthood from the environment [10-11]. 60 
Several clinical studies suggest that adaptive humoral immune responses, in 61 
particular to TcdA and TcdB, may influence clinical outcomes of CDI [12]. Most 62 
notably, a landmark study in 2000 reported that a low IgG titre to TcdA, but not 63 
TcdB, at the time of infection is associated with development of symptomatic 64 
disease [13]. More recently, the same group demonstrated an association 65 
between median IgG titres to TcdA and 30-day all-cause mortality [14]. Several 66 
reports have also assessed antibody responses following infection and shown 67 
protection against recurrence associated with antibody responses to TcdA, TcdB 68 
and several non-toxin antigens (Cwp66, Cwp84, FliC, FliD and the surface layer 69 
proteins) [15-18]. By contrast, other studies have reported that humoral immune 70 
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responses did not influence the clinical course of CDI [18-21].  These conflicting 71 
reports may be attributed to heterogeneity in study design and subject 72 
populations. Although the role of humoral immunity remains incompletely 73 
understood, vaccination strategies using inactivated toxins or recombinant toxin 74 
fragments are currently the subject of intense investigation [22-23]. More 75 
recently, the possibility of adding other vaccine targets such as surface-76 
associated proteins and polysaccharides to toxin combinations is gaining traction, 77 
and could be of added value in the prevention of C. difficile colonization and 78 
disease transmission [22-23]. It is likely that the design of these next generation 79 
multicomponent vaccines targeting colonization, persistence and toxin production 80 
will stimulate the requirement for evaluating humoral immune responses to 81 
multiple antigens.  82 
 83 
The enzyme-linked immunosorbant assay (ELISA) is the traditional method of 84 
accurately quantifying antibodies with different specificities in epidemiologic 85 
research and vaccine development as well as in the diagnosis of allergies, 86 
autoimmune and infectious diseases. We and other groups [13, 15, 18-20] have 87 
independently developed and used a traditional standardized ELISA format for 88 
the purposes of determining human specific IgG responses against C. difficile 89 
antigens (toxins). However, ELISA based tests can be time-consuming and 90 
require large quantities of both sample and reagents, thus limiting their potential 91 
for high-throughput use [23-24]. ELISA offers only monoplex data, or results of a 92 
single protein per assay (typically TcdA, TcdB or SLPs) and from a single C. 93 
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difficile strain. Additional concerns include the lack of a uniform standard for 94 
calibration purposes and thus no generally accepted way of expressing ELISA 95 
units, as well as poor consistency between protocols and reagents, including 96 
notably the quality and source of antigens. Moreover, the linear region of the 97 
dynamic range is highly platform dependent.  98 
Recently, protein microarrays, a miniaturized version of a sandwich ELISA, have 99 
evolved as a promising tool for quantifying specific antibodies directed against 100 
various microbial antigens in human sera, and may be an attractive alternative to 101 
conventional ELISA assays in determining antigen-specific antibody responses 102 
[25-31]. Microarray assays have potentially important advantages compared with 103 
standard ELISA formats. These include a much increased capacity for 104 
multiplexing detection of a range of specific antibodies due to the flexibility of 105 
array printing of multiple antigens per array over a single protein, vastly reduced 106 
requirements for antigens, serum and reagents, increased assay robustness due 107 
to increased technical replication within each assay, multiple internal quality 108 
control measures and improved quality control capabilities. The unique 109 
capabilities of microarray including parallelism, high-throughput and 110 
miniaturization are ideally suited to comprehensive investigation of the humoral 111 
immune response to the entire proteome of an infectious agent consisting of 112 
thousands of potential antigens, in a patient-specific manner [29]. Microarray 113 
technology can also be applied to the development of improved serodiagnostic 114 
tests, discovery of subunit vaccine antigen candidates, epidemiological research 115 
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and vaccine development, in addition to providing novel insights into infectious 116 
disease and the immune system [29].   117 
 118 
We have developed and validated a novel customized microarray platform that 119 
enables the simultaneous quantification of systemic IgG immune responses to a 120 
7-plex panel of highly purified C. difficile-specific virulence factors, including 121 
whole toxins A and B, recombinant fragments of toxin A (TxA4) and toxin B 122 
(TxB4), type-specific surface layer proteins and suitable control proteins. We 123 
compared the performance of the microarray technique with a conventional 124 
ELISA using an established panel of sera. 125 
 126 
 127 
Materials and Methods 128 
 129 
Microbial proteins and serum samples 130 
Highly purified whole toxins A and B (toxinotype 0, strain VPI10463, ribotype 087) 131 
in addition to recombinant toxin fragments TxA4 and TxB4, (comprising central 132 
and receptor binding domains and both based on toxinotype 0 sequences), were 133 
obtained from Public Health England, UK (Dr Clifford Shone). Purified 134 
polymerase chain reaction (PCR) ribotype-specific native whole SLPs (001, 002, 135 
027) were provided by Dublin City University, Eire (Professor Christine Loscher). 136 
Positive controls incorporated on each plate included tetanus toxoid and lysates 137 
from Candida albicans containing the cytoplasm and cell wall.   138 
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Negative controls included spotted printing buffer (PBS Trehalose Tween) and no 139 
serum (blank) on each array. 140 
 141 
Banked sera from adult patients with CDI [n=150; median age 67 years (range 142 
19-98 years], a group of patients with cystic fibrosis (CF) without diarrhea [n=17 143 
where 2 of these patients were found to be asymptomatic carriers; median age 144 
28 (19-49 years)] and healthy controls [n=67; median age 36 years (22-65 145 
years)] were used to investigate the ability of the microarray assay to detect the 146 
presence or absence of IgG directed against C. difficile microbial and control 147 
antigens. Adult healthy donors were recruited from within the hospital and 148 
University workforce setting. All the patients in the CDI group had diarrhea 149 
(defined as a change in bowel habit with 3 or more unformed stools per day for at 150 
least 48 hours) and positive stool C. difficile toxin test. Asymptomatic carriers 151 
were defined as those without diarrhea, but had a positive stool culture for C. 152 
difficile. The diagnosis of CF had previously been made on the basis of a positive 153 
sweat test and/or demonstration of 2 known CF mutations and typical clinical 154 
features of disease (without a history of CDI). All subjects provided written 155 
informed consent under approvals granted by the Nottingham Research Ethics 156 
Committee. 157 
 158 
Preparation and processing of arrayed antigens 159 
 160 
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Microbial antigens were diluted to 200μg/ml in printing buffer (PBS Trehalose 161 
Tween) in a 384-well plate (Genetix) and spotted in quadruplicate in a 16 x 16 162 
array format onto poly-L-Lysine-coated glass slides (Electron Microscopy 163 
Sciences) using a Biorobotics MicroGridlI arrayer (Microgrid 610, Digilab, 164 
Malborough, MA, USA) in addition to 15 human serial IgG dilutions (range 50 165 
μg/ml – 3.05 ng/ml) to create a calibration curve. The slides were blocked with 166 
5% BSA diluted in PBS-Tween (PBST; PBS containing 0.05% Tween-20) wash 167 
buffer for 1 hour at room temperature (RT) with shaking. After washing 5 times 168 
for 3 minutes each with PBST, all slides were incubated with sera diluted 1:500 in 169 
antibody diluent (Dako) for 1 hour. Following washing, the slides were incubated 170 
with biotinylated anti-human IgG (Vector Labs) diluted 1:20,000 in antibody 171 
diluent for 1 hour. After further washing, slides were incubated with Streptavidin 172 
Cy5 (ebioscience) diluted 1:2000 in 5% BSA for 15 minutes. After a final wash 173 
with PBST followed by distilled water, slides were dried by centrifugation at 500 g 174 
for 4 minutes. Unless stated otherwise, all wash steps were carried out at RT with 175 
shaking. Slides were scanned using a GenePix 4200AL scanner, a PMT of 450 176 
and 100% power. The resultant TIFF images were processed with Axon Genepix 177 
Pro-6 Microarray Image Analysis software (Molecular Services Inc.) to obtain 178 
fluorescence data for each feature and generate gpr files. Protein signals were 179 
finally determined with background subtraction using RPPanalyzer, a module 180 
within the R statistical language on the CRAN (http://cran.r-project.org/) [33] 181 
 182 
Statistical analysis 183 
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Antibody levels were calculated using GraphPad Prism 6.0 Software. As data 184 
collected for antibody measurements were not normally distributed, non-185 
parametric tests were employed with medians and ranges calculated. For 186 
comparison of multiple groups, Kruskall Wallis one-way ANOVA was used with 187 
Dunn’s post-test. Correlation was evaluated using the Spearman rank correlation 188 
coefficient test.  P values of <0.05 were considered to represent  statistically 189 
significant differences. 190 
 191 
Results 192 
Quality control measures 193 
Internal QC measures on each array were devised to support inter-assay 194 
normalization, assay performance and data acquisition machine performance 195 
monitoring. These measures included the addition of a replicated serial dilution of 196 
human IgG to verify function of the detection system and provide a standard 197 
curve of human IgG against which antibody responses could be calibrated. 198 
Antigens from 2 known human pathogens (tetanus toxoid and Candida albicans), 199 
where the majority of normal individuals would be expected to have some 200 
existing protective antibody response were incorporated onto each array. These 201 
positive control antigens were examined for each array as an indicator of sample 202 
integrity. Figure 1 shows a plot of the responses seen in 327 serum samples for 203 
each of the 2 control antigens. Strong responses are seen to tetanus toxoid and 204 
Candida albicans. Negative controls were also incorporated onto each array as a 205 
further internal QC measure. 206 
 10
 207 
Microarray Intra- and Inter-assay Precision 208 
 209 
Microarray intra-and inter-assay variability was calculated using the sera of 7 210 
patients. Identical samples were assayed on each of two slides at two 211 
independent time points. All antigens were spotted in replicates of five on each 212 
array. In the case of intra-assay variation, all 7 test and 2 control antigens fell 213 
within acceptable limits of precision [coefficient of variation (CV)  <10%; toxin A 214 
7.76%, toxin B 6.39%, SLP001 7.44%, SLP002 5.19%, SLP027 7.64%, TxA4 215 
7.03%, TxB4 3.71%, tetanus 4.21%, candida 8.28%]. The inter-assay coefficient 216 
of variation for each antigen was calculated as 7.76%, 6.39%, 7.44%, 5.19%, 217 
7.64%, 7.03%, 3.71%, 4.21% and 8.26%, respectively.  218 
 219 
Correlation between Microarray and ELISA assay results 220 
 221 
Due to the lack of validated and commercially available quantitative and 222 
standardized IgG ELISAs targeting toxins A and B or other C. difficile-associated 223 
antigens, we compared specific IgG anti-toxin A and anti-toxin B antibody 224 
measurements generated by microarray versus previously obtained in-house 225 
indirect ELISA readings using the same patient test sera [21]. Spearman 226 
correlation coefficient was used to assess the level of agreement between the 227 
two platforms and results are visually represented in Figure 2. When comparing 228 
the microarray performance with the in-house ELISA assays, a good correlation 229 
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coefficient was observed for toxin A (r= 0.7051; p<0.0001) with a moderately 230 
good correlation for toxin B (r= 0.5809 p<0.0001).  231 
 232 
Sensitivity and specificity 233 
Sensitivity and specificity of individual and panels of antibody response to C. 234 
difficile-specific antigens were calculated for both the CDI and CF groups using 235 
selected age-matched samples and the same panel of 7 antigens (Toxin A, Toxin 236 
B, SLP001, SLP002, SLP027, TxA4 and TxB4) based upon the same cut-off of 237 
95th percentile of the control samples. CF samples have a sensitivity and 238 
specificity of 75% and 100% respectively while the figures for CDI are 25% and 239 
100% respectively. 240 
 241 
Serum antibody reactivity profiles using microarray 242 
 243 
A total of 327 serum samples were tested by microarray for the presence of 244 
specific IgG antibody. The microarray assay was able to detect specific antibody 245 
responses to all C. difficile antigens including recombinant toxin fragments tested 246 
(example response to native antigens demonstrated in Figure 3). The signals 247 
from positive control proteins (tetanus and candida) were similar in healthy 248 
control individuals, patients with CF and CDI. Each array also included negative 249 
controls (buffer only and no serum or blank) which gave no signal. The reactivity 250 
of these spots was routinely subtracted from all signals obtained from specific 251 
antigens. The microarrays detected significantly higher levels of specific 252 
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antibodies in the CF group across all C. difficile antigens tested compared with 253 
healthy control and with CDI sera (Figure 4). In the CDI group, antibody 254 
responses to whole (Figure 4A and B) and recombinant toxins A and B (Figure 5) 255 
did not differ compared with the healthy control group, but infected patients did 256 
exhibit significantly lower anti-SLP IgG levels (all ribotypes) compared with 257 
controls and with patients with CF (Figure 4C). No statistically significant 258 
differences were observed in specific antibody levels to any of the antigens 259 
comparing single and relapsing CDI sera (data not presented).  260 
 261 
 262 
Discussion 263 
 264 
Current knowledge of the complete antigen repertoire recognized by patients 265 
during CDI is sparse, limiting a detailed interrogation of immunity, exposure and 266 
hindering preclinical vaccine development. The goal of this study was to develop, 267 
validate and implement a novel protein microarray readout assay that allows the 268 
accurate, precise, and reproducible quantification of specific antibody responses 269 
to a selected panel of C. difficile-specific microbial antigens using a pre-existing 270 
bank of test sera.  271 
 272 
This study represents, to our knowledge, the first report of highly purified anti-273 
SLP 001, 002 and 027 IgG responses in a large cohort of patient sera and 274 
extends the usefulness of immunoassay techniques through simultaneous 275 
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examination of multiple C. difficile-specific antigens including toxins in one 276 
immunoassay layout. We demonstrate that serum C. difficile antigen-specific IgG 277 
antibody responses can be detected using this technique, and that the magnitude 278 
and breadth of response to individual specific microbial antigens differs greatly 279 
between individuals and patient groups.  280 
 281 
Whilst our assay achieved excellent specificity for the target panel of antigens 282 
analysed, lower detection sensitivity was observed, particularly for the CDI group. 283 
Importantly, antibody-based serological assays are hampered by the high 284 
likelihood or prior exposure to micro-organisms encountered in the environment.  285 
In this regard, all populations previously exposed to C. difficile bacterial antigens 286 
will produce seropositive responses. Nevertheless, it should be possible to 287 
enhance sensitivity for specific antibody detection through probing the 288 
microarrays with a larger bank of longitudinal (acute and convalescent) test sera 289 
and/or activated B lymphocyte supernatant samples which secrete antigen-290 
specific antibodies from patients with symptomatic CDI [21] and healthy controls 291 
who do not carry C. difficile in their stool. In addition, detection sensitivity may be 292 
improved by pooling several antigenic targets specific for C. difficile. 293 
 294 
In contrast to previous studies asserting that development of symptomatic CDI 295 
may be correlated with low IgG titres to toxin A but not to toxin B, our data do not 296 
demonstrate any significant differences in IgG anti-toxin A or IgG anti-toxin B 297 
levels in CDI patients compared to healthy controls. Similarly, other investigators 298 
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have either reported no disparities or higher serum anti-toxin A IgG levels in CDI 299 
patients compared to controls [11, 19, 34]. Although the carriage rate of C. 300 
difficile in the control subjects was not known, the lack of difference may have 301 
arisen due to the fact that most of the healthy control subjects in this study were 302 
recruited from a pool of hospital and University co-workers. As such, it is likely 303 
that natural asymptomatic exposure to toxigenic C. difficile was a more common 304 
occurrence and thus may be due to transient colonization. Furthermore, we 305 
acknowledge that patients in the CDI group were also older compared to 306 
individuals in the CF and control groups. However, other investigators have 307 
shown that serum antibody levels were not affected by age [13, 15].  It will be of 308 
interest to determine whether specific qualitative and quantitative differences in T 309 
and B cell responses to C. difficile and its antigens account for higher prevalence 310 
of CDI in older populations. 311 
 312 
Notably, significantly higher anti-toxin and anti-SLP IgG antibody concentrations 313 
in patients with CF (with no previous history of CDI) are likely to be due to more 314 
frequent contact with the toxins and SLPs of C. difficile which occur with 315 
colonization (especially after admission to hospital) and following antibiotic-316 
mediated disruption of the protective resident microflora. Indeed, two of the 317 
patients with CF were asymptomatic carriers of C. difficile. Furthermore, this 318 
particular small cohort of CF patients also had additional risk factors for C. 319 
difficile colonization/infection, including tube feeding (n=5), and the use of proton 320 
pump inhibitors (n =14). 321 
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 322 
Whilst firm conclusions cannot be drawn because of the small number of subjects 323 
studied, our present data suggest that the host’s ability to mount a robust 324 
antibody response to multiple C. difficile-specific protein antigens as seen in the 325 
CF group, may help confer protection from developing symptomatic CDI. 326 
Protection from symptomatic CDI may be a higher order phenomenon related to 327 
patterns of antibody response as opposed to being attributable to any single 328 
antigenic target. Notably, CDI is rarely seen in CF patients despite the presence 329 
of multiple risk factors for infection, including frequent exposures to antibiotics 330 
and hospitals. Several studies have also shown that patients with CF are often 331 
asymptomatic carriers of C. difficile [35-38] with one recent report indicating that 332 
most strains carried by CF patients were non-toxigenic (77% versus 17%) [38]. It 333 
is also possible that colonization with non-toxigenic C. difficile may protect 334 
against colonization with toxin-producing strains and/or that differences in colonic 335 
mucus or the microbiome may also contribute to protection in the CF population. 336 
Understanding the role of the gut microbiota in programming the immune 337 
phenotype in the context of CF may offer a series of interactive windows that 338 
could be aligned to prevent CDI. Further detailed studies that aim to dissect the 339 
complex dialogue between the host, immune system and intestinal microbiota are 340 
currently underway in a larger cohort of CF patients.  341 
 342 
Limitations of the present study are the small sample of strain-specific bacterial 343 
proteins employed, unequal sample sizes in the different groups studies, lack of 344 
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age matching, the absence of colonizing/immunizing strain information, the study 345 
of only one isotype, the lack of antibody neutralization data and the absence of 346 
ELISA and microarray correlation data for the recombinant toxin fragments and 347 
non-toxin antigens examined. Whether or not the immunogenicity of these latter 348 
selected antigens contributes to CDI protection remains to be fully determined. 349 
We observed a lower correlation between microarray and ELISA in the toxin B 350 
assays (r=0.58; P<0.0001). This finding was particularly apparent at increasing 351 
IgG anti-toxin B concentrations and may mean that ELISA lacks accuracy at 352 
higher specific anti-toxin B IgG concentrations. Discordance between both 353 
methods could also be an effect of the low throughput of ELISA that requires the 354 
samples to be analyzed in small batches over a longer period of time; by 355 
contrast, the high-throughput array platforms permits analysis of large sample 356 
cohorts under similar experimental conditions in a much more rapid time frame, 357 
likely enhancing result reproducibility. Discrepancies between both technologies 358 
may also have arisen due to variations in the quality of sera and toxins over time, 359 
especially when new batches/different sources of toxin were tested. These 360 
results also suggest that mapping temporal changes in serological responses to 361 
C. difficile may be best undertaken using high-throughput methods such as 362 
protein microarray. 363 
 364 
In summary, we verify that this initial design and implementation of a protein 365 
microarray platform is well suited to identify, quantify and compare multiple 366 
specific antigenic responses following challenge by C. difficile. Given that 367 
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antigenic variation occurs between different strains, host responses may well 368 
vary according to which are the prevalent strains. High-throughput assays will be 369 
important in measuring the heterogeneity of host immune responses. 370 
Modifications of this microarray approach could be employed to expand the 371 
antigen targets to include proteins derived from multiple strains of C. difficile in 372 
addition to investigating multiple isotype specificities. The microarray platform 373 
could also be adapted to study cytokine/chemokine repertoires in response to 374 
infection or vaccination for large collections of individual patient sera. Optimised 375 
immunological marker panels are yet to be developed for predicting host 376 
responses to C. difficile. Before advancements can be made, more detailed 377 
careful studies in larger well defined prospective cohorts will be required before 378 
this C. difficile antigen-specific microarray assay can be used as a prognostic tool 379 
as well as tailoring interventional strategies. Nevertheless, protein microarrays 380 
have the potential to provide a more comprehensive antigen-specific humoral 381 
immune response profile in vaccinated or infected humans, that could find 382 
beneficial applications in large-scale sero-epidemiological, longitudinal and sero-383 
surveillance analyses 384 
 385 
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Figure Legends.  513 
Figure 1. Testing sample integrity of all serum samples using two positive control 514 
antigens: Tetanus toxoid and Candida albicans antigen. Strong responses are 515 
seen to both antigens from all the samples. 516 
Figure 2. Correlation between microarray and ELISA IgG anti-toxin A (A) and 517 
IgG anti-toxin B (B) antibody levels in patients with C. difficile infection and in 518 
patients with cystic fibrosis without a history of diarrhoea. Each dot represents a 519 
serum sample from an individual patient. Spearman correlation coefficient tests 520 
revealed significant agreement between both assay results (*** denotes P < 521 
0.0001). Abbreviations: ELISA, enzyme-linked immunosorbent assay; IgG, 522 
immunoglobulin G. 523 
Figure 3. Selected serum IgG responses to C. difficile proteins on microarray. 524 
Green (low) to red (high) signal intensity heat map representing the relative IgG 525 
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response to C. difficile immunoreactive antigens (native toxins A and B, and 526 
ribotype-specific surface layer proteins 001, 002, 027) in different serum samples 527 
from patients infected with C. difficile, CF patients and healthy controls.  528 
Figure 4. Anti-toxin A (A) and anti-toxin B (B) IgG responses in healthy controls 529 
subjects and patients with C. difficile infection and a group of patients with cystic 530 
fibrosis and no history of diarrhoea. Differences between groups were calculated 531 
using the Kruskall-Wallis test followed by Dunn's post test for multiple 532 
comparisons. Horizontal lines in each graph represent the median. (C) Patients 533 
with cystic fibrosis had significantly higher levels of specific IgG antibody levels to 534 
toxins A and B compared to healthy controls and patients with C. difficile 535 
infection. In the microarray assays, there were significantly lower anti-SLP IgG 536 
levels across all ribotypes tested (001, 002, 027) in patients with C. difficile 537 
infection compared to patients with cystic fibrosis  and healthy controls (*** 538 
denotes p ≤0.001, ** denotes p ≤0.01, * denotes p ≤0.05). Abbreviations: SLP, 539 
surface layer protein. 540 
Figure 5. Anti-TxA4 and anti-TxB4 IgG responses in healthy controls, patients 541 
with C. difficile infection and in a CF group of patients with no history of 542 
diarrhoea. Differences between groups were calculated using the Kruskall-Wallis 543 
test followed by Dunn's post test for multiple comparisons. Horizontal lines in 544 
each graph represent the median. In the microarray assays, CF patients 545 
displayed significantly higher IgG levels against both recombinant toxin 546 
fragments compared to healthy controls and patients with C. difficile infection (*** 547 
denotes p ≤0.001) . 548 
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